Teva Pharmaceutical Industries (NYSE:TEVA) Issues Q1 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) updated its first quarter 2025 earnings guidance on Friday. The company provided earnings per share guidance of 0.520-0.520 for the period, compared to the consensus earnings per share estimate of 0.480. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion. Teva Pharmaceutical Industries also updated its FY 2025 guidance to 2.350-2.650 EPS.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded up $0.31 during midday trading on Monday, reaching $15.39. 16,417,970 shares of the company traded hands, compared to its average volume of 12,319,464. The firm's 50 day simple moving average is $17.21 and its two-hundred day simple moving average is $18.12. The firm has a market cap of $17.44 billion, a PE ratio of -10.61, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries has a 1-year low of $12.51 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts have issued reports on TEVA shares. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Thursday. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Finally, Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and a consensus price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.